

Leqvio - Guide to using video - HCP

[Prescribing information](#)

Image



Image



Guide to using LEQVIO®▼ (inclisiran)



GUIDE TO USING LEQVIO® inclisiran

LEQVIO® (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet¹

- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated

LDL-C – low-density lipoprotein cholesterol.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

LEQVIO® is intended for administration by a healthcare professional.
For detailed instructions for use, please see the package leaflet.

Prescribing information can be found on the web page on which this video is shown.
Promotional material produced and funded by Novartis for UK healthcare professionals only.

Reference: 1. LEQVIO® Summary of Product Characteristics.

UK | December 2024 | FA-11303613



VIDEO

A short video explaining how to administer LEQVIO®, including step-by-step instructions for injection.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://www.pro.novartis.com/uk-en/medicines/cardio-metabolic/leqvio/resources/using-leqvio-video>